All In Biotech

NDA 020065 · Bausch and Lomb

Opcon-A

Naphazoline Hydrochloride, Pheniramine Maleate · Ophthalmic

Last checked: Nov 19, 2026Latest source record: Sep 23, 2022 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1994

Jun 8, 1994

Approved uses

1

Original approval plus efficacy supplements

Registered trials

8

4 Phase 3, 0 recruiting

FAERS reports

1,660

86 serious, 8 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Sep 28, 2026.

Uses temporarily relieves itching and redness caused by pollen, ragweed, grass, animal hair and dander.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jun 8, 1994 Original approval · Type 5 - New Formulation or New Manufacturer
1 products under this application
  • OPCON-A · NAPHAZOLINE HYDROCHLORIDE 0.02675%; PHENIRAMINE MALEATE 0.315% · SOLUTION/DROPS, OPHTHALMIC · Over-the-counter

Clinical trials

Interventional ClinicalTrials.gov studies with "Naphazoline" as an intervention, any sponsor and status, largest first.

All 8 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • mydriasis446
  • eye irritation425
  • vision blurred214
  • drug ineffective206
  • eye pain158
  • ocular hyperaemia149
  • instillation site pain104
  • condition aggravated74
  • eye pruritus66
  • lacrimation increased60
  • eye swelling48
  • visual impairment47

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20041
20052
20062
20071
2008114
2009137
2010126
2011148
2012126
2013105
201488
201570
2016128
2017132
201825
201974
202044
202118
202250
202375
202449
202572
202673

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 24 on PubMed

Sponsor: Bausch and Lomb

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.